Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread

作     者：Lyu, Ning Kong, Yanan Pan, Tao Mu, Luwen Li, Shaolong Liu, Yaru Deng, Haijing Li, Jibin Shi, Ming Xu, Li Guo, Rongping Chen, Minshan Wu, Peihong Zhao, Ming 

作者机构：Sun Yat Sen Univ Canc Ctr Dept Minimally Invas Intervent Radiol 651 Dongfeng Rd East Guangzhou 510060 Guangdong Peoples R China Sun Yat Sen Univ Canc Ctr Dept Med Imaging 651 Dongfeng Rd East Guangzhou 510060 Guangdong Peoples R China Sun Yat Sen Univ Canc Ctr Dept Breast Oncol Ctr Med Imaging & Intervent Radiol 651 Dongfeng Rd East Guangzhou 510060 Guangdong Peoples R China Sun Yat Sen Univ Canc Ctr State Key Lab Oncol South China Dept Clin Res 651 Dongfeng Rd East Guangzhou 510060 Guangdong Peoples R China Sun Yat Sen Univ Canc Ctr Dept Hepatobiliary Oncol 651 Dongfeng Rd East Guangzhou 510060 Guangdong Peoples R China Sun Yat Sen Univ Affiliated Hosp 3 Dept Vasc Intervent Radiol Guangzhou Guangdong Peoples R China 

出 版 物：《JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY》 (血管与介入放射学杂志)

年 卷 期：2019年第30卷第3期

页      面：349-357页

核心收录：

学科分类：0831[工学-生物医学工程（可授工学、理学、医学学位）] 100207[医学-影像医学与核医学] 1006[医学-中西医结合] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 08[工学] 1010[医学-医学技术（可授医学、理学学位）] 100106[医学-放射医学] 1009[医学-特种医学] 10[医学] 100602[医学-中西医结合临床] 

主　　题：CI confidence interval CR complete response EHS extrahepatic spread FU fluorouracil HAI hepatic arterial infusion HAIC hepatic arterial infusion chemotherapy HBV hepatitis B virus HCC hepatocellular carcinoma HR hazard ratio LV leucovorin MVI macrovascular invasion ORR objective response rate OS overall survival OXA oxaliplatin PR partial response SD stable disease 

摘      要：Purpose: To compare treatment with hepatic arterial infusion of chemotherapy (HAIC) in patients with advanced hepatocellular carcinoma (HCC) with both extrahepatic spread (EHS) and intrahepatic tumor and patients with intrahepatic tumor only. Materials and Methods: This single-center retrospective study comprised 116 patients with advanced HCC with both intrahepatic tumor and EHS (EHS group;n = 50) or with intrahepatic tumor only (non-EHS group;n = 66) treated with HAIC including oxaliplatin, fluorouracil, and leucovorin between June 2014 and July 2016. Overall survival (OS) and radiologic responses to treatment were determined and compared between the 2 groups. Results: Both the objective response rate and the clinical benefit rate were higher in the non-EHS group than in the EHS group (37.9% vs 16% objective response rate, P =.010;81.8% vs 62% clinical benefit rate, P = .017). Median OS was not statistically different between the 2 groups (14.8 months vs 9.8 months, P = .068). Subgroup analysis of OS found Mat patients with lung metastases survived for a shorter time (OS 7 months) than patients with other metastatic sites (P = .003) and patients free of metastases (P = .001). Conclusions: HAIC is a potential treatment option for advanced HCC with limited extrahepatic metastases in a population with hepatitis B virus infection.